TACSTD2 and neoplasm: However, traditional ADCs that target receptors expressed on both tumor cells and certain non-malignant tissues (such as EGFR and TROP2) are often associated with unavoidable on-target off-tumor toxicities, leading to dose reductions or treatment discontinuation [5, 6].